Study of Milnacipran for the Treatment of Fibromyalgia

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.

ClinicalTrials.gov Identifier: NCT00314249

Recruitment Status : Completed

First Posted : April 13, 2006

Results First Posted : November 2, 2009

Last Update Posted : January 20, 2010

Sponsor:

Collaborator:

Cypress Bioscience, Inc.

Information provided by:

Forest Laboratories

Study Description

Brief Summary:

The purpose of this study was to demonstrate the efficacy and safety of milnacipran at a dosage of 100 mg/day in the treatment of the fibromyalgia syndrome or the pain associate with fibromyalgia.

Condition or disease	Intervention/treatment	Phase
Fibromyalgia	Drug: Placebo Drug: Milnacipran 100mg	Phase 3

Study Design


Study Type :	Interventional (Clinical Trial)
Actual Enrollment :	1025 participants
Allocation:	Randomized
Intervention Model:	Parallel Assignment
Masking:	Double (Participant, Investigator)
Primary Purpose:	Treatment
Official Title:	A Phase III Pivotal, Multicenter, Double-blind, Randomized, Placebo-Controlled Monotherapy Study of Milnacipran for the Treatment of Fibromyalgia.
Study Start Date :	April 2006
Actual Primary Completion Date :	June 2008

Resource links provided by the National Library of Medicine

Genetics Home Reference related topics: Fibromyalgia

MedlinePlus related topics: Fibromyalgia

Drug Information available for: Milnacipran Levomilnacipran Milnacipran hydrochloride

U.S. FDA Resources

Arms and Interventions

Arm	Intervention/treatment
Placebo Comparator: Placebo Placebo, oral administration, twice daily for 12 weeks	Drug: Placebo Placebo, oral administration, twice daily for 12 weeks
Experimental: Milnacipran Milnacipran 100mg/day (50mg BID [twice a day])	Drug: Milnacipran 100mg Milnacipran 100mg per day (50mg BID [twice a day])

Outcome Measures

Primary Outcome Measures :

Composite Syndrome Responder Status [ Time Frame: At the end of the three-month stable dose treatment phase ]
Composite Pain Responder Status [ Time Frame: At the end of three-month stable dose treatment phase ]

Secondary Outcome Measures :

Time-Weighted Average of Patient Experience Diary (PED) Reported Morning 24-Hour Recall Pain Scores for Weeks 1-12 of the Stable Dose Phase [ Time Frame: Weeks 1 through 12 of the stable dose treatment phase (Visit TX0-TX12) ]
Time-Weighted Average of Patient Global Impression of Change (PGIC) From Visit TX0-TX12. [ Time Frame: Weeks 1-12 (Visit TX0-TX12) of the stable dose treatment phase ]
Change From Baseline in the Multi-Dimensional Fatigue Inventory (MFI) Total Score at Visit TX12. [ Time Frame: Baseline through end of week 12 (Visit TX12) ]
Time-Weighted Average of the Short Form-36 Physical Component Summary (SF-36 PCS) Score From Visit TX0-TX12 [ Time Frame: Weeks 1-12 (Visit TX0-TX12) of the stable dose treatment phase ]

Eligibility Criteria

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Ages Eligible for Study:	18 Years to 70 Years (Adult, Older Adult)
Sexes Eligible for Study:	All
Accepts Healthy Volunteers:	No

Criteria

Inclusion Criteria:

diagnosis of fibromyalgia defined by 1990 American College of Rheumatology (ACR) Criteria

Exclusion Criteria:

psychiatric illness,
depression,
suicidal risk,
substance abuse,
pulmonary dysfunction,
renal impairment,
active cardiac disease,
liver disease,
autoimmune disease,
cancer,
inflammatory bowel disease

Contacts and Locations

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT00314249

Show 24 Study Locations

Sponsors and Collaborators

Forest Laboratories

Cypress Bioscience, Inc.

More Information

Publications automatically indexed to this study by ClinicalTrials.gov Identifier (NCT Number):

Saxe PA, Arnold LM, Palmer RH, Gendreau RM, Chen W. Short-term (2-week) effects of discontinuing milnacipran in patients with fibromyalgia. Curr Med Res Opin. 2012 May;28(5):815-21. doi: 10.1185/03007995.2012.677418. Epub 2012 Apr 10.

Arnold LM, Gendreau RM, Palmer RH, Gendreau JF, Wang Y. Efficacy and safety of milnacipran 100 mg/day in patients with fibromyalgia: results of a randomized, double-blind, placebo-controlled trial. Arthritis Rheum. 2010 Sep;62(9):2745-56. doi: 10.1002/art.27559.


Responsible Party:	Robert Palmer, MD, Forest Research Institute, a subsidiary of Forest Laboratories, Inc.
ClinicalTrials.gov Identifier:	NCT00314249 History of Changes
Other Study ID Numbers:	MLN-MD-03
First Posted:	April 13, 2006 Key Record Dates
Results First Posted:	November 2, 2009
Last Update Posted:	January 20, 2010
Last Verified:	January 2010

Keywords provided by Forest Laboratories:


Fibromyalgia

Additional relevant MeSH terms:


Fibromyalgia Myofascial Pain Syndromes Muscular Diseases Musculoskeletal Diseases Rheumatic Diseases Neuromuscular Diseases Nervous System Diseases Milnacipran Antidepressive Agents Psychotropic Drugs	Serotonin Uptake Inhibitors Neurotransmitter Uptake Inhibitors Membrane Transport Modulators Molecular Mechanisms of Pharmacological Action Neurotransmitter Agents Serotonin Agents Physiological Effects of Drugs Adrenergic Uptake Inhibitors Adrenergic Agents

To Top